Journal
CURRENT DIABETES REPORTS
Volume 19, Issue 4, Pages -Publisher
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-019-1136-3
Keywords
Hypertriglyceridemia; Type 2 diabetes; Diabetic dyslipidemia; Medications
Categories
Funding
- VHA Health Services Research Development [CDA 13-261]
- Center of Innovation to Accelerate Discovery and Practice Transformation [CIN 13-410]
- National Institutes of Health [T32DK007012]
Ask authors/readers for more resources
Purpose of ReviewModerate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)the diabetic dyslipidemia phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients.Recent FindingsIn the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population.SummaryEmerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available